摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-1-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2 (1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-1-one | 1456692-54-8

中文名称
——
中文别名
——
英文名称
(S)-1-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2 (1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-1-one
英文别名
1-[2-[(1S)-8-(hydroxymethyl)-7-methylsulfonyl-1-propan-2-yl-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-2-yl]-4-(trifluoromethyl)pyrimidin-5-yl]propan-1-one
(S)-1-(2-(8-(hydroxymethyl)-1-isopropyl-7-(methylsulfonyl)-3,4-dihydrobenzo[4,5]imidazo[1,2-a]pyrazin-2 (1H)-yl)-4-(trifluoromethyl)pyrimidin-5-yl)propan-1-one化学式
CAS
1456692-54-8
化学式
C23H26F3N5O4S
mdl
——
分子量
525.552
InChiKey
HLMVLEINLZPXPH-IBGZPJMESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    36
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    127
  • 氢给体数:
    1
  • 氢受体数:
    11

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS FOR USE IN TREATING RETT SYNDROME
    申请人:Vitae Pharmaceuticals, Inc.
    公开号:US20160113930A1
    公开(公告)日:2016-04-28
    Provided herein are compounds and pharmaceutically acceptable salts thereof that are useful therapeutics for Rett syndrome.
    本文提供了对Rett综合征有用的化合物及其药用盐。
  • LIVER X RECEPTOR MODULATORS
    申请人:Vitae Pharmaceuticals, Inc.
    公开号:US20150065515A1
    公开(公告)日:2015-03-05
    Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.
    本文提供了一些新颖的化合物及其药学上可接受的盐,它们是肝X受体调节剂。同时,本文还提供了包含本发明化合物和载体的组合物。此外,还描述了使用本文化合物和治疗与肝X受体相关的疾病或失调的方法。
  • COMBINATION OF A MC1R RECEPTOR AGONIST AND UVB FOR THE TREATMENT AND/OR PREVENTION OF PIGMENTATION DISORDERS
    申请人:Galderma Research & Development
    公开号:EP2825187A1
    公开(公告)日:2015-01-21
  • COMPOUNDS FOR USE IN TREATING ACUTE CORONARY SYNDROME AND RELATED CONDITIONS
    申请人:Vitae Pharmaceuticals, Inc.
    公开号:US20170231992A1
    公开(公告)日:2017-08-17
    Provided herein are compounds and pharmaceutically acceptable salts thereof that are useful therapeutics for acute coronary syndrome and related disorders.
  • METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS
    申请人:The Rockefeller University
    公开号:US20190029984A1
    公开(公告)日:2019-01-31
    The invention features methods of treating disorders related to increased levels of myeloid derived suppressor cells such as cancer or infections. The disclosure also provides methods of treating cancer including combinations of LXRβ agonists and immunotherapies such as PD1 inhibitors, PDL1 inhibitors, and adoptive T-cell transfer therapy.
查看更多